

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

GE HEALTHCARE LTD.,
Petitioner

v.

THE JOHNS HOPKINS UNIVERSITY,
Patent Owner

Case PGR2025-00059
U.S. Patent No. 12,115,233

PATENT OWNER'S UPDATED EXHIBIT LIST

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Patent Owner The Johns Hopkins University (“Patent Owner”) submits this Updated Exhibit List to accompany submission of Exhibit 2060, the transcript of a teleconference held between the Board and parties on July 27, 2026.

PATENT OWNER’S UPDATED EXHIBIT LIST

Exhibit No.	Description
2001	Declaration of Dr. Henry VanBrocklin in Support of Patent Owner Preliminary Response
2002	<i>Curriculum vitae</i> of Dr. Henry VanBrocklin
2003	Jansen <i>et al.</i> , “Selective inhibitors of fibroblast activation protein (FAP) with a xanthine scaffold,” <i>MedChemComm</i> (August 2014) (“Jansen 2014”)
2004	Sikkandhar <i>et al.</i> , “Theranostic Probes for Targeting Tumor Microenvironment: An Overview,” <i>International Journal of Molecular Sciences</i> (May 2017) (“Sikkandhar”)
2005	<i>Intentionally Left Blank</i>
2006	Isherwood <i>et al.</i> , “Live Cell <i>in Vitro</i> and <i>in Vivo</i> Imaging Applications: Accelerating Drug Discovery,” <i>Pharmaceutics</i> (April 2011) (“Isherwood”)
2007	<i>Intentionally Left Blank</i>
2008	Loktev <i>et al.</i> , “Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention,” <i>The Journal of Nuclear Medicine</i> (October 2019) (“Loktev”)
2009	Nishida <i>et al.</i> , “Angiogenesis in cancer,” <i>Vascular Health and Risk Management</i> (September 2006) (“Nishida”)

Exhibit No.	Description
2010	Seaman <i>et al.</i> , “Molecular imaging agents: impact on diagnosis and therapeutics in oncology,” <i>Expert Reviews in Molecular Medicine</i> (July 2010) (“Seaman”)
2011	Slania <i>et al.</i> , “Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinyloxy)-glycyl-2 cyanopyrrolidine-Based Small Molecules,” <i>Journal of Medicinal Chemistry</i> (April 2021) (“Slania”)
2012	Xu <i>et al.</i> , “Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy,” <i>The Journal of Nuclear Medicine</i> (June 2022) (“Xu”)
2013	Zboralski <i>et al.</i> , “Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition,” <i>European Journal of Nuclear Medicine and Molecular Imaging</i> (July 2023) (“Zboralski”)
2014	<i>Intentionally Left Blank</i>
2015	U.S. Patent No. 11,938,201 (“the ’201 patent”)
2016	VanBrocklin <i>et al.</i> “ $^{16}\beta$ -([^{18}F]Fluoro)estrogens: Systematic Investigation of a New Series of Fluorine-18-Labeled Estrogens as Potential Imaging Agents for Estrogen-Receptor-Positive Breast Tumors,” <i>Journal of Medicinal Chemistry</i> (May 1993) (“VanBrocklin 1993”)
2017	VanBrocklin <i>et al.</i> “Anilinodialkoxyquinazolines: Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Potential Tumor Imaging Probes,” <i>Journal of Medicinal Chemistry</i> (October 2005) (“VanBrocklin 2005”)
2018	Errata to Declaration of Dr. Brian Zeglis (EX1003)

Exhibit No.	Description
2019	Zeglis <i>et al.</i> , “Radiopharmaceuticals for Imaging in Oncology with Special Emphasis on Positron Emitting Agents,” Chapter 3 of <i>Nuclear Oncology: Pathophysiology and Clinical Applications</i> , H.W. Strauss <i>et al.</i> , eds. (2013) (“Zeglis 2013 II”)
2020	Poplawski <i>et al.</i> , “Identification of Selective and Potent Inhibitors of Fibroblast Activation Protein and Prolyl Oligopeptidase,” <i>J Med Chem.</i> 56(9): 3467–3477 (May 9, 2013) (“Poplawski”)
2021	Pages 7 and 8 of U.S. Patent Application Publication No. 2010/0098633 A1 (EX1004) (annotated by Dr. Brian Zeglis)
2022	Pages 12–14 of U.S. Patent Application Publication No. 2010/0098633 A1 (EX1004) (annotated by Dr. Brian Zeglis)
2023	Transcript of the Deposition of Dr. Brian Zeglis, March 11, 2026
2024	Sugiura <i>et al.</i> , “Radiolabeling Strategies for Tumor-Targeting Proteinaceous Drugs,” <i>Molecules</i> 19: 2135–2165 (2014) (“Sugiura”)
2025	Testa <i>et al.</i> , “The influence of lipophilicity on the pharmacokinetic behavior of drugs: Concepts and examples,” <i>Perspectives in Drug Discovery and Design</i> , 19: 179–211 (2000) (“Testa”)
2026	Siwowska <i>et al.</i> , “Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo Properties,” <i>Molecular Pharmaceutics</i> , 14(2): 523–532 (2017) (“Siwowska”)
2027	Hall, H.K., “Correlation of the Base Strengths of Amines,” <i>Journal of the American Chemical Society</i> , 79(20): 5441–5444 (October 20, 1957) (“Hall”)
2028	Fischer <i>et al.</i> , “Radioimmunotherapy of Fibroblast Activation Protein Positive Tumors by Rapidly Internalizing Antibodies,” <i>Clinical Cancer Research</i> , 18(22): 6208–6218 (November 15, 2012) (“Fischer”)

Exhibit No.	Description
2030	Scott <i>et al.</i> , “A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer,” <i>Clinical Cancer Research</i> , 9: 1639–1647 (May 2003) (“Scott”)
2031	Welt <i>et al.</i> , “Antibody Targeting in Metastatic Colon Cancer: A Phase I Study of Monoclonal Antibody F19 Against a Cell-Surface Protein of Reactive Tumor Stromal Fibroblasts,” <i>Journal of Clinical Oncology</i> , 12(6): 1193–1203 (June 1994) (“Welt”)
2032	Aertgeerts <i>et al.</i> , “Structural and Kinetic Analysis of the Substrate Specificity of Human Fibroblast Activation Protein α ,” <i>The Journal of Biological Chemistry</i> , 280(20): 19441–19444 (May 20, 2005) (“Aertgeerts”)
2033	Laverman <i>et al.</i> , “Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis,” <i>The Journal of Nuclear Medicine</i> , 56(5): 778–783 (May 2015) (“Laverman”)
2034	Däpp <i>et al.</i> , “PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with ^{177}Lu -DOTA-bombesin analogues,” <i>EJNMMI Research</i> , 2 (June 9, 2012) (“Däpp”)
2035	Rüger <i>et al.</i> , “ <i>In vivo</i> near-infrared fluorescence imaging of FAP-expressing tumors with activatable FAP-targeted, single-chain Fv-immunoliposomes,” <i>Journal of Controlled Release</i> , 184: 1–10 (2014) (“Rüger”)
2036	LeBeau <i>et al.</i> , “Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin,” <i>Molecular Cancer Therapy</i> , 8(5): 1378–1386 (May 2009) (“LeBeau”)
2037	Huang <i>et al.</i> , “Evaluation of the tumor targeting of a FAP α -based doxorubicin prodrug,” <i>Journal of Drug Targeting</i> , 19(7): 487–496 (2011) (“Huang”)

Exhibit No.	Description
2038	Keane <i>et al.</i> , “Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein- α ,” <i>FEBS Journal</i> , 278: 1316–1332 (2011) (“Keane”)
2039	Reiner <i>et al.</i> , “Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging,” <i>Journal of Visualized Experiments</i> , 96 (February 2015) (“Zeglis 2015”)
2040	Adumeau <i>et al.</i> , “Site-Specifically Labeled Immunoconjugates for Molecular Imaging—Part 1: Cysteine Residues and Glycans,” <i>Molecular Imaging Biology</i> , 18: 1–17 (2016) (“Zeglis 2016”)
2041	Zeglis <i>et al.</i> , “Chemoenzymatic Strategy for the Synthesis of Site-Specifically Labeled Immunoconjugates for Multimodal PET and Optical Imaging,” <i>Bioconjugate Chemistry</i> , 25(12): 2123–2128 (November 24, 2014) (“Zeglis 2014”)
2042	Penner <i>et al.</i> , “Radiolabeled Absorption, Distribution, Metabolism, and Excretion Studies in Drug Development: Why, When, and How?” <i>Chemical Research in Toxicology</i> , 25: 513–531 (2012) (“Penner”)
2043	Rablen, P., “Typical Electron-Withdrawing Groups Are ortho, meta-Directors Rather than meta-Directors in Electrophilic Aromatic Substitution,” <i>The Journal of Organic Chemistry</i> , 90(17): 6090–6093 (2025) (“Rablen”)
2044	Petri <i>et al.</i> , “Pyrrolidine in Drug Discovery: A Versatile Scaffold for Novel Biologically Active Compounds,” <i>Topics in Current Chemistry</i> , 379(34) (2021) (“Petri”)
2045	Bvumbi, M., “Activity of Riminophenazines against Mycobacterium tuberculosis: A Review of Studies that Might be Contenders for Use as Antituberculosis Agents,” <i>ChemMedChem</i> , 15: 2207–2219 (2020) (“Bvumbi”)

Exhibit No.	Description
2046	Xu <i>et al.</i> , “Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors,” <i>Bioorganic & Medicinal Chemistry Letters</i> , 15(10): 2533–2536 (2005) (“Xu”)
2047	Calcaterra <i>et al.</i> , “Classics in Chemical Neuroscience: Diazepam (Valium),” <i>ACS Chemical Neuroscience</i> , 5(4): 253–260 (2014) (“Calcaterra”)
2048	Kim <i>et al.</i> , “A New Class of SN2 Reactions Catalyzed by Protic Solvents: Facile Fluorination for Isotopic Labeling of Diagnostic Molecules,” <i>Journal of the American Chemical Society</i> , 128(50): 16394–16397 (2006) (“Kim”)
2049	Westaway <i>et al.</i> , “Determining the Transition-State Structure for Different SN2 Reactions Using Experimental Nucleophile Carbon and Secondary alpha-Deuterium Kinetic Isotope Effects and Theory,” <i>Journal of Physical Chemistry A</i> , 112: 10264–10273 (2008) (“Westaway”)
2050	Basha <i>et al.</i> , “Therapeutic potential of pyrrole and pyrrolidine analogs: an update,” <i>Molecular Diversity</i> , 26(5): 2915–2937 (2022) (“Basha”)
2051	Wilbur, D., “Radiohalogenation of Proteins: An Overview of Radionuclides, Labeling Methods, and Reagents for Conjugate Labeling,” <i>Bioconjugate Chemistry</i> , 3(6): 433–470 (1992) (“Wilbur”)
2052	Glaser <i>et al.</i> , “Radiosynthesis and Biodistribution of Cyclic RGD Peptides Conjugated with Novel [¹⁸ F]Fluorinated Aldehyde-Containing Prosthetic Groups,” <i>Bioconjugate Chemistry</i> , 19: 951–957 (2008) (“Glaser”)
2053	Hsieh <i>et al.</i> , “Direct Solid-Phase Synthesis of Octreotide Conjugates: Precursors for Use as Tumor-Targeted Radiopharmaceuticals,” <i>Bioorganic & Medicinal Chemistry</i> , 7(9): 1797–1803 (1999) (“Hsieh”)

Exhibit No.	Description
2054	Haider <i>et al.</i> , “Emerging Pharmaceutical Applications of Piperidine Pyrrolidine and its Derivatives,” <i>World Journal of Pharmaceutical Research</i> , 3(7): 987–1024 (2014) (“Haider”)
2055	Pichon <i>et al.</i> , “Synthesis of 2,5-Disubstituted Pyrrolidines,” <i>Tetrahedron: Asymmetry</i> , 7(4): 927–964 (1996) (“Pichon”)
2056	Dukat <i>et al.</i> , “Pyrrolidine-modified and 6-substituted analogs of nicotine: a structure-affinity investigation,” <i>European Journal of Medicinal Chemistry</i> , 31: 875–888 (1996) (“Dukat”)
2057	Zeglis <i>et al.</i> “Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics,” <i>Molecular Pharmaceutics</i> , 12: 3575–3587 (2015) (“Zeglis 2015 II”)
2058	Supporting Information for Exhibit 2011 (“Slania”) (<i>served not filed</i>)
2059	Supporting Information for Exhibit 2003 (“Jansen 2014”) (<i>served not filed</i>)
2060	Teleconference Transcript, July 27, 2026

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX PLLC

/Christopher M. Gallo/

Christopher M. Gallo, Ph.D.
Registration No. 70,291
Back-up Counsel for Patent Owner

Date: August 10, 2026

1101 K Street, NW, 10th Floor
Washington, DC 20005
(202) 371-2600

CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e))

I certify that the above-captioned **PATENT OWNER'S UPDATED EXHIBIT LIST** and associated Exhibit 2060 were served in their entirety on August 10, 2026, upon the following parties via electronic mail:

Jeffrey P. Kushan (Lead Counsel)
Lauren Katzeff (Back-up Counsel)
Amit Bhatla (Back-up Counsel)
SIDLEY AUSTIN LLP
jkushan@sidley.com
lkatzeff@sidley.com
abhatla@sidley.com

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX PLLC

/Christopher M. Gallo /

Christopher M. Gallo, Ph.D.
Registration No. 70,291
Back-up Counsel for Patent Owner

Date: August 10, 2026

1101 K Street, NW
10th Floor
Washington, DC 20005
(202) 371-2600